Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TILIM

Financiado

Cerrado

The T cell immune response against latent infection with Mycobacterium tuberculo...

The T cell immune response against latent infection with Mycobacterium tuberculosis One third of the world's population is infected with latent TB, which therefore constitutes the largest reservoir for TB. In 5% of latently infected individuals TB will eventually re-activate, and it is believed that most new TB c... ver más

31/12/2012

SSI

207K€

Presupuesto del proyecto: 207K€

Líder del proyecto

STATENS SERUM INSTITUT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2012-12-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

SSI

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PCIN-2013-041 UNA APROXIMACION OMICA AL DIAGNOSTICO DE LA TUBERCULOSIS Cerrado

MART Mucosal antibody and B cell responses during Tuberculosis 203K€ Cerrado

IMAGING TB Deciphering mycobacterial subversion of early steps of adapt... 269K€ Cerrado

PathCO Pathogen COinfection HIV Tuberculosis Malaria and Hepatiti... 8M€ Cerrado

SAF2017-84839-C2-1-R EL FENOTIPO SILENTE DE MYCOBACTERIUM TUBERCULOSIS: PERSISTEN... 109K€ Cerrado

HOMITB Host and microbial molecular dissection of pathogenesis and... 4M€ Cerrado

Líder del proyecto

STATENS SERUM INSTITUT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 207K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto One third of the world's population is infected with latent TB, which therefore constitutes the largest reservoir for TB. In 5% of latently infected individuals TB will eventually re-activate, and it is believed that most new TB cases is indeed due to re-activation of latent TB. TB is a chronic disease, and during the long interaction with the host, the immune response against TB antigens tend to focus on only a few dominant epitopes. The idea for the project is that while a response against the dominant epitopes will lead to partial protection, it is not enough to eradicate M.tb resulting in a lifelong latent infection. Moreover, a response against dominant epitopes will wane with time resulting in re-activation of TB, and spreading of the disease. As a consequence, an immune response against only dominant epitopes within M.tb antigens is not enough to fully control the infection and stop the spread of the disease. Recently is has become increasingly clear that concerning chronic diseases, responses against subdominant epitopes, not induced by the natural infection, can be highly protective (1), and our working hypothesis is therefore the following: To increase the control over a chronic persisting M.tb infection (and prevent re-activation of TB), a response against the subdominant epitopes is required. To examine this we intend to test the vaccine efficacy of both dominant epitopes (epitopes induced by the natural infection) and sub-dominant epitopes (epitopes not induced by the natural infection) given post exposure to animals harbouring a persistent infection.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores